SAROJA PHARMA INDUSTRIES LIMITED

The Corporate Identification Number of our Company is U24110MH2010PLC135190.

Our Company was originally incorporated as “Sarova Pharma Industries India Private Limited” on 14th January, 2010 under the provisions of the Companies Act, 2013 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai, Maharashtra. Later on, our company converted into public limited company, the name of our Company has changed to “SAROJA PHARMA INDUSTRIES India Limited” and fresh Certificate of Incorporation dated 16th April, 2023 has been issued by the Registrar of Companies, Mumbai Maharashtra. Corporate Identification Number of our Company is U24110MH2010PLC135190.

Registered office: 306, Kailash Tower, Shiv Shri Silk Complex, Goregaon Link Road, Mulund West, Mumbai, MAHARASHTRA - 400080

Corporate Office: Shop No. 209, 2nd Floor, Eccost, City of Joy, Jata Shankar Dosa Marg, Mulund West, Mumbai, MAHARASHTRA- 400080

Website: www.sarovaipharmaceuticals.com

E-mail: info@sarovaipharmaceuticals.com

Website: www.sarovaipharmaceuticals.com

Telephone: +91 (22) 2801 0011

Company Secretary and Compliance Officer: Ms. Nikita Kumar

PROMOTER’S OF OUR COMPANY: MR. Biju Gopinathan Nair and MR. Manish Dassharath Kambale

THE ISSUE

PUBLIC ISSUE OF UPTO 10,81,880 EQUITY SHARES OF FACE VALUE OF ₹1/- EACH OF SAROJA PHARMA INDUSTRIES INDIA LIMITED ("SAROJA" OR THE "COMPANY") FOR THE PURPOSE OF THIS ISSUE CASH AT A PRICE OF ₹1/- PER EQUITY SHARE INCLUDING A BAND PRIME OF ₹0.75 PER EQUITY SHARE AND SUBJECT TO A MAXIMUM AGGREGATING TO ₹4.92 LAKHS WILL BE RESERVED FOR MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION") (M.T.S. OF ISSUE) AND 7,08,543 EQUITY SHARES OF FACE VALUE OF ₹1/- EACH AGGREGATING TO ₹7.08 LAKHS IS HEREAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 25.95% AND 25.35% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 1/- EACH AND THE ISSUE PRICE IS ₹ 4.84/-.

UPDATION AVAILABLE IN ASBA FOR RETAIL INVESTORS

For details on the ASBA and updation process, please refer to the details given in Asba form and Alongside Prospectus and please refer to the section “Issue Procedure” beginning on page no. 293 of the Prospectus.

This process is also available on the website of National Stock Exchange of India Limited (www.nseindia.com), in General Information Document. List of Banks Supporting ASBA is also available on the website of ASBA (www.nsedirect.com).

CREDIT RATING:

As a result of this Issue, the Equities Shares will be credited to the investor’s demat account on the closing date.

ELIGIBILITY TO APPLY:

As an issuer of Equity Share, the promoters are not in the business of rating or giving any type of rating.

PROPOSED LISTING

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE"). In terms of Chapter II of the SEBI (ICDR) Regulations, 2015, as amended from time to time, our Company has received in-principle approval dated 10th August, 2023 from National Stock Exchange of India Limited ("NSE") for using its name in this offer for listing of our shares on the EMERGE Platform of National Stock Exchange of India Limited. For the purpose of this issue, the Designated Stock Exchange will be NSE.

DESCRIPTION OF SHARES

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with SEBI. However SEBI shall not issue any observation on the Draft Prospectus. Hence investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

DISCLAIMER OF NSE

"It is to be distinctly understood that the permission given by NSE shall not in any way be deemed or construed that the Prospectus has been cleared or approved by NSE nor does it certify the correctness or adequacy of any of the contents of the Prospectus.

In the event of NSE issuing any notice or order to this effect in the future, the disclaimer given herein shall become effective immediately.

DISCLAIMER OF NSE

"It is to be distinctly understood that the permission given by NSE shall not in any way be deemed or construed that the Prospectus has been cleared or approved by NSE nor does it certify the correctness or adequacy of any of the contents of the Prospectus.

In the event of NSE issuing any notice or order to this effect in the future, the disclaimer given herein shall become effective immediately.

Table: Listing

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Name of Shareholders</th>
<th>Number of Shareholders</th>
<th>Number of Shares</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Mr. Biju Gopinathan Nair</td>
<td>7,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Mr. Manish Dassharath Kambale</td>
<td>3,000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The Present Capital structure of the Company is as follows:

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE"). In terms of Chapter II of the SEBI (ICDR) Regulations, 2015, as amended from time to time, our Company has received in-principle approval dated 10th August, 2023 from National Stock Exchange of India Limited ("NSE") for using its name in this offer for listing of our shares on the EMERGE Platform of National Stock Exchange of India Limited. For the purpose of this issue, the Designated Stock Exchange will be NSE.

These offers are made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015 and Draft Offer Document have not been filed with Sebi. However, Sebi shall not issue any observation on the draft prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.

Since the issue is being made in terms of Chapter II of the SEBI (ICDR) Regulations, 2015, the Drafts Offer Document had not been filed with Sebi. However, Sebi shall not issue any observation on the Draft Prospectus. Hence, investors may refer full text of the "DISCLAIMER OF CLAUSE B OF ISSUE" beginning page no. 195 of the Prospectus.
The FACE VALUE OF THE EQUITY SHARES IS ₹ 10/-. EACH AND THE ISSUE PRICE IS ₹ 84/-. THE ISSUE PRICE IS 0.4 TIMES THE FACE VALUE.

ONPENS ON: THURSDAY, 31 AUGUST, 2023
CLOSED ON: TUESDAY, 05 SEPTEMBER, 2023

1,600 EQUITY SHARES FOR RETAIL INVESTORS
3,200 EQUITY SHARES IN MULTIPLE OF 1,600 EQUITY SHARES THEREFTER FOR HNI/ QIB CATEGORY

For details on the ASBA and upi process, please refer to the details given in the ASBA form and Abide Prospectus and please refer to the section "ISSUE PROCEDURE" beginning on page no. 203 of the Prospectus. The process is also available on the website of National Stock Exchange of India Limited (www.seiind.com), in General Information Document. List of Banks Supporting UPI is also available on the website of SEI (www.seiind.com).

Additional Information

- **CREDIT RATING**: As is the issue of Equity Shares is fundamentally credit-worthy for this issue.
- **EQUITY TRUSTEE**: As these are an issue of Equity Shares, the appointment of Trustees is not required.
- **APPRAISAL**: Since the issue is being mentioned in Chapters of the SEBI (IPO) Regulations, 2012, there is no requirement of an annual appraising of theesti CAGR. The stock is also not an investment in an established industry.
SAROJA PHARMA INDUSTRIES INDIA LIMITED
The Corporate Identification Number of our Company is U24110MH1995PLC019386
Our Company was originally incorporated as “Saroja Pharma Industries India Limited” on 14th January, 1995 under the provisions of the Companies Act, 1956 with a Certificate of Incorporation issued by the Registrar of Companies, Mumbai, Maharashtra. Later on, company was converted into public limited company, the name of our Company has changed to “Saroja Pharma Industries India Limited” and fresh Certificate of Incorporation dated 18th April, 2003 has been issued by the Registrar of Companies, Mumbai, Maharashtra. Corporate Identification number of our Company is U24110MH1995PLC019386.
Corporate Office: Shop No. 209, 2nd Floor, Ecotasty, City of Joy, Jala Shankar Dosa Marg, Mulund West, Mumbai, MAHARASHTRA - 400080
Website: www.sarojapharma.com | E-mail: info@sarojapharma.com | Telephone: +91 (022) 2801 0011
Company Secretary and Corporate Officer: Ms. Nikita Kumar

**THE ISSUE**

**PUBLICATION OF THE ISSUE**

PUBLICATION OF THE ISSUE

Saroja Pharma Industries India Limited ("SAROJA" or the "COMPANY") is issuing a fresh issue of Equity Shares of face value of Rs.10/- each. Each Equity Share will be allotted to the applicants at a price of Rs. 18/- per Equity Share.

The issue comprises of 1,60,000 Equity Shares of Rs.10/- each aggregating to Rs. 1,60,00,000. The application is open from 17th March 2023 and closes on 05th September 2023. The price band of the issue is fixed between Rs. 15/- and Rs. 20/-. The Dynamex Securities Limited ("Dynamex") will act as the CMA of the issue.

**THESE TERMS OF ISSUE**

For further details see “TERMS OF THE ISSUE” beginning on page no. 195 of the Prospectus.

**THE FACE VALUE OF THE EQUITY SHARES IS Rs.10/- EACH AND THE ISSUE PRICE IS Rs. 18/-. THE ISSUE PRICE IS 8.64 TIMES OF THE FACE VALUE.**

**UPI NOW AVAILABLE IN ASIA FOR RETAIL INDIVIDUAL INVESTORS**

For details on the UPI and UPI process, refer to the details given in ASBA term and ADRIPose Prospectus and please see the relevant “ISSUE PROCEDURE” beginning on page no. 203 of the Prospectus.

The process is also available on the website of National Stock Exchange of India Limited (www.nseindia.com), in General Information Document.

(Continued on Page 195)

**Credit Rating**

As an issue of Equity Shares being referred to the Issuer for Rating.

**DEMONETIZATION.DISCLAIMER**

The contents of this document are for information purposes only and shall not be construed as an invitation to buy or sell securities or as investment advice. The contents of this document have been prepared in good faith on the basis of publicly available information. Neither the Issuer nor any of its officers, directors, employees, associates shall be liable for any loss, damage or injury, whether direct or consequential, that may arise out of use or reliance on the contents of this document.

**NOTICE TO SHAREHOLDERS**

In connection with the issue, the Board of Directors of the Company have appointed the promoter, Shri. Bilu Gandhi, as the person responsible for the preparation of the issue. The Board of Directors have appointed Associate Director, Mr. R. K. Gandhi, as the person responsible for the preparation of the issue. The Board of Directors have appointed Associate Director, Mr. R. K. Gandhi, as the person responsible for the preparation of the issue. The Board of Directors have appointed Associate Director, Mr. R. K. Gandhi, as the person responsible for the preparation of the issue. The Board of Directors have appointed Associate Director, Mr. R. K. Gandhi, as the person responsible for the preparation of the issue.

Certified by: R. K. Gandhi
Company Secretary
27.09.2023

**NOTICE TO THE INVESTORS**

This document contains forward-looking statements that are not historical facts. These statements are made based on current expectations, estimates, projections, and assumptions and, as such, are subject to change as circumstances and conditions change. The Company disclaims any obligation to update these statements. No representation or warranty, express or implied, is made as to the accuracy of any forward-looking statements contained herein.